Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

β-Secretase-1: In Silico Drug Reposition for Alzheimer’s Disease

3 May 2023

Abstract excerpt

-secretase-1 enzyme (BACE-1) performs a key role in the production of beta-Amyloid protein (Aβ), which is associated with the development of Alzheimer's disease (AD). The inhibition of BACE-1 has been an important pharmacological strategy in the treatment of this neurodegenerative disease. This study aims to identify new potential candidates for the treatment of Alzheimer's with the help of in silico studies,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholinesterase and Neurodegenerative Diseases
Share to Macrophage Migration Inhibitory Factor
Share to Natural Antidiabetic Agents Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37175873
DOI: 10.3390/ijms24098164

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

β-Secretase-1: In Silico Drug Reposition for Alzheimer’s DiseasePMID 37175873Read ↗

Dual Inhibitors of AChE and BACE-1 for Reducing Aβ in Alzheimer’s Disease: From In Silico to In VivoSemantic proximity Read ↗

Machine Learning-Enhanced Drug Discovery for BACE1: A Novel Approach to Alzheimer's TherapeuticsSemantic proximity Read ↗

BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's diseaseSemantic proximity Read ↗

Identification of dual inhibitors against BACE1 and GSK-3β for the treatment of Alzheimer’s disease: An in silico-based approachSemantic proximity Read ↗

Computational Prioritization of Multi-Target Inhibitors: Explainable QSAR and Docking- Based Discovery of Dual AChE/BACE1 ChemotypesSemantic proximity Read ↗

African Natural Products for Multitarget-Based Treatment of Alzheimer’s Disease: An In Silico StudySemantic proximity Read ↗

<strong> </strong> Exploring the Therapeutic Potential of Hypericin: Molecular Docking with ABAD and BACE1 targets in Alzheimer's Disease PathogenesisSemantic proximity Read ↗

Structural Analysis of Simultaneous Activation and Inhibition of γ-Secretase Activity in Development of Drugs for Alzheimer’s diseaseSemantic proximity Read ↗

Identification of new BACE1 inhibitors for treating Alzheimer’s diseaseSemantic proximity Read ↗

Small-Molecule Amyloid Beta-Aggregation Inhibitors in Alzheimer's Disease Drug DevelopmentSemantic proximity Read ↗

Identifying Unexpected Therapeutic Targets via Chemical-Protein InteractomeSemantic proximity Read ↗

Network Pharmacology-guided Identification and Molecular Validation of Multi-Target Phytoconstituents from Gmelina arborea against Alzheimer’s DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.